N-[[3-[8-methyl-5-methylamino-8H-imidazo[4,5-d]thiazolo[5,4-b]-pyridine-2-yl]phenyl]methyl]-tert-butyl carbamate | 1134816-48-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: N-[[3-[8-methyl-5-methylamino-8H-imidazo[4,5-d]thiazolo[5,4-b]-pyridine-2-yl]phenyl]methyl]-tert-butyl carbamate
• CAS: 1134816-48-0
• 化学式: C₂₁H₂₄N₆O₂S
• 分子量: 424.527
• InChiKey: HIRUDWBMBQJJLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.31
• 重原子数：
  30.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  93.96
• 氢给体数：
  2.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  N-[[3-[8-methyl-5-methylamino-8H-imidazo[4,5-d]thiazolo[5,4-b]-pyridine-2-yl]phenyl]methyl]-tert-butyl carbamate 在 盐酸 、 水 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.33h， 以105 mg的产率得到2-[3-(aminomethyl)phenyl]-N,8-dimethyl-8H-imidazo[4,5-d]-thiazolo[5,4-b]pyridine-5-amine
  参考文献：
  名称：

  Novel Tricyclic Inhibitors of IκB Kinase

  摘要：

  The design and synthesis of a novel series of oxazole-, thiazole-, and imidazole-based inhibitors of I kappa B kinase (IKK) are reported. Biological activity was improved compared to the pyrazolopurine lead, and the expedient synthesis of the new tricyclic systems allowed for efficient exploration of structure-activity relationships. This, combined with an iterative rat cassette dosing strategy, was used to identify compounds with improved pharmacokinetic (PK) profiles to advance for in vivo evaluation.

  DOI：

  10.1021/jm8015816
• 作为产物：
  描述：

  N-[[3-[8-methyl-5-chloro-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]-tert-butyl carbamate 、 甲胺 以 乙醇 为溶剂， 反应 0.17h， 生成 N-[[3-[8-methyl-5-methylamino-8H-imidazo[4,5-d]thiazolo[5,4-b]-pyridine-2-yl]phenyl]methyl]-tert-butyl carbamate
  参考文献：
  名称：

  Novel Tricyclic Inhibitors of IκB Kinase

  摘要：

  The design and synthesis of a novel series of oxazole-, thiazole-, and imidazole-based inhibitors of I kappa B kinase (IKK) are reported. Biological activity was improved compared to the pyrazolopurine lead, and the expedient synthesis of the new tricyclic systems allowed for efficient exploration of structure-activity relationships. This, combined with an iterative rat cassette dosing strategy, was used to identify compounds with improved pharmacokinetic (PK) profiles to advance for in vivo evaluation.

  DOI：

  10.1021/jm8015816